| Clinical Input |
|
|
| Response |
|
|
| Percentage of patients achieving response (complete or partial) |
84.48
|
30.017
|
| Percentage of patients dead before assessment of response |
7.48
|
25.017
|
| Percentage of patients achieving no response |
8.28
|
45.017
|
| Stem cell transplantation |
|
|
| Percentage of patients who receive stem cell transplantation |
10.5 |
14.8 |
| Adverse events |
|
|
| Cytokine release syndrome (grade III or higher) |
49 |
0 |
| Hypogammaglobulinemia (B-cell aplasia) |
43 |
0 |
| Utilities |
|
|
| Alive and not responding to treatment |
0.7518
|
0.7518
|
| Alive and responding to treatment |
0.9118
|
0.9118
|
| Long-term survivor—alive |
0.9118
|
0.9118
|
| Cytokine release syndrome (grade III or higher) |
014 for 8 d19
|
014 for 8 d19
|
| Disutilities |
|
| Chemotherapy |
−0.42 for duration of treatment20
|
–0.42 for duration of treatment20
|
| Stem cell transplantation |
−0.57 for duration of treatment20
|
−0.57 for duration of treatment20
|
| Economic Inputs, 2017 US $ |
| Treatment acquisition cost (with markup)$ |
|
| Tisagenlecleucel |
575 000 |
575 000 |
| Clofarabine |
264 per mg/mL21
|
264 per mg/mL21
|
| Methotrexate |
0.09 per mg/mL21
|
0.09 per mg/mL21
|
| Fludarabine |
3.70 per mg/mL21
|
3.70 per mg/mL21
|
| Cyclophosphamide |
0.74 per mg/mL21
|
0.74 per mg/mL21
|
| Cytarabine |
0.02 per mg/mL21
|
0.02 per mg/mL21
|
| Etoposide |
0.09 per mg/mL21
|
0.09 per mg/mL21
|
| Tocilizumab |
7.69 per mg/mL21
|
7.69 per mg/mL21
|
| Intravenous immunoglobulin |
0.14 per mg/mL21
|
0.14 per mg/mL21
|
| Healthcare use costs, $ |
|
| Cost per hospital day |
404922
|
404922
|
| Cost per day in intensive care unit |
404922
|
404922
|
| Office visit |
7423
|
7423
|
| Intravenous treatment administration (first hour) |
14023
|
14023
|
| Intravenous treatment administration (each additional hour) |
2923
|
2923
|
| Intravenous treatment administration (each additional sequence or drug) |
6623
|
6623
|
| Hematology panel |
1123
|
1123
|
| Liver function test |
823
|
823
|
